Loading clinical trials...

COMPLETED

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

NCT07058051•AbbVie

Summary

The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.

Detailed Description

Cross-Sectional

Eligibility

Age

12 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female patients, age ≥ 12.
•Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI\<50) with or without facial involvement.
•Medical history available within the last 6 months.
•Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and \< 18 years of age at inclusion visit).
•Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.

Exclusion Criteria

•Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
•Segmental or localized vitiligo.
•Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
•History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
•Patients who are participating in interventional clinical trial(s) at time of study visit.
•Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.

Locations (4)

Dermatology Hospital of Southern Medical University /ID# 276921

Guangzhou, Guangdong, China

Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 276919

Wuhan, Hubei, China

Suzhou Municipal Hospital /ID# 276948

Suzhou, Jiangsu, China

Shandong Dermatological Hospital /ID# 276918

Jinan, Shandong, China

Key Dates

Start Date

July 17, 2025

Primary Completion Date

November 13, 2025

Completion Date

November 13, 2025

Last Updated

November 19, 2025

Enrollment

100

ACTUAL participants

Conditions

Non-Segmental Vitiligo

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177

Non-segmental Vitiligo

View study

RECRUITINGPHASE4

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients

NCT06991972

VitiligoNon-segmental Vitiligo

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

Inclusion Criteria

Exclusion Criteria

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)